Trials / Unknown
UnknownNCT04407845
Atrial Fibrillation in Patients Receiving Ibrutinib
Etude de l'Incidence et Des Facteurs prédictifs de la Survenue de Fibrillation Atriale Sous Ibrutinib
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- European Georges Pompidou Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ibrutinib (a tyrosine kinase inhibitor targeting Bruton) is a standard of treatment in haematology. According to retrospective data, atrial fibrillation and systemic hypertension are common ibrutinib-related advserse events. The investigators aim at prospectively establishing the incidence of thesedrug related advsere events through clinical monitoring and attempt at identifying populations at risk.
Conditions
Timeline
- Start date
- 2020-05-21
- Primary completion
- 2022-05-21
- Completion
- 2022-11-30
- First posted
- 2020-05-29
- Last updated
- 2020-06-09
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04407845. Inclusion in this directory is not an endorsement.